title: Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors.
abstract: OBJECTIVE
  Sorafenib, a drug that inhibits Raf serine/threonine kinases mediating cell proliferation and receptor tyrosine kinases involved in angiogenesis, is approved for treatment of advanced hepatocellular carcinoma. The study aims to evaluate the efficacy and analyze the prognostic factors of sorafenib treatment in patients with advanced hepatocellular carcinoma (HCC).
  
  
  METHODS
  Consecutive cases of HCC were treated with sorafenib (400 mg, Bid). Baseline clinical parameters, adverse events and survival were collected.
  
  
  RESULTS
  A total of 60 patients received sorafenib and transarterial therapy. There was no CR; 2 (3.3%) patients achieved partial response, but 30 patients (50.0%) achieved stable disease. The median follow-up time was 16 months. The median OS and median TTP were 13.6 months and 4.4 months respectively. The common adverse events were dermal reaction (60.0%, 36/60), diarrhea (46.7.0%, 28/60), hypertension (5.0%, 3/60), hair loss (16.7%, 10/60), myelosuppression (20.0%, 12/60), and liver dysfunction (25.0%, 15/60). In most patients, these side effects were mild-to-moderate, and alleviated remarkably after symptomatic treatment. The patients with lower tumor burden and without extrahepatic spread had better prognosis.
  
  
  CONCLUSIONS
  Soafenib is effective for unresectable primary HCC with tolerable toxicity. Tumor stage is a predominant prognostic factor.
authors.forename: Jinpeng
authors.initials: J
authors.lastname: Li
authors.forename: Lijun
authors.initials: L
authors.lastname: Wang
authors.forename: Ning
authors.initials: N
authors.lastname: Cong
authors.forename: Congcong
authors.initials: C
authors.lastname: Shi
authors.forename: Wenzhe
authors.initials: W
authors.lastname: Bu
authors.forename: Jinlong
authors.initials: J
authors.lastname: Song
authors.forename: Hua
authors.initials: H
authors.lastname: Chen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000201:enzymology / Q000401:mortality / Q000556:secondary; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018579:Patient Selection; D010671:Phenylurea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D016016:Proportional Hazards Models; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D018570:Risk Assessment; D012307:Risk Factors; D000077157:Sorafenib; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib